SOLID TUMOURS

SOLID TUMOURS

Oncology Imaging is one of IAG’s special areas of therapeutic expertise and focus.  Oncology studies comprise almost one third of IAG’s clinical development experience. Currently IAG is engaged in trials with umbrella, adaptive and basket trial designs. IAG is providing full imaging service and image review in early and late phase trials, bringing our world-wide site network, operational expertise and technology platform DYNAMIKA to manage, collect, hold and score the imaging data.

A large proportion of our studies are the early clinical and phase II studies in solid tumours, lymphomas and brain tumours.

IAG’s radiology and analytics teams have hands-on experience with state-of-the-art imaging scoring systems and novel AI-driven methodologies. We have worked with studies requiring MRI, CT, X-ray, PET, immunoPET, SPECT, US, histology, and fluoroscopy imaging. Specifically, our team is board certified and experienced in:

  • RECIST1.1, iRECIST, mRECIST, irRC, irRECIST,
  • PERCIST and EORTC criteria for PET response,
  • CHOI criteria for response to tumours,
  • Macdonald, RANO, iRANO, mRANO and RAPNO for Neuro-Oncology,
  • PIRADS and PCWG3 criteria for Prostate cancer,
  • Cheson, Lugano and RECIL for lymphoma,
  • Olsen criteria; IWCLL for CLL; MDA for bone metastases.

IAG’s team is an active scientific contributor and our work involved development of quantitative methodologies for

  • Pseudo progression measurements
  • Radiomic Analyses
  • Quantitative assessment of the lesions (texture, shape, heterogeneity)
  • Use of advanced imaging to assess the perfusion, hypoxia, cellular density of the tumours
  • Macrophage Analysis
  • Automated quantitation of total tumour burden and volumetric analysis
  • Use of PET / SPECT novel agents for immune trafficking and receptor imaging

Our experts often use advanced functional imaging to aid early assessment of treatment response in oncology trials. These include:

  • Perfusion measurements
  • Diffusion and cellular density measurements
  • Metabolic and proliferation assessments

We have experience with radiotherapies and advanced therapies, including

  • Cellular therapy
  • Viral therapy
  • Intra tumoral injection
  • Vaccines
  • Combination studies
  • Ablative therapy, radiation therapy
  • Immune system stimulators
  • Radiotherapies

IAG’s in-house radiologists and experts in Artificial Intelligence, Machine Learning and Big Data analytics can assist with all aspects of the imaging trial design, imaging data collection, site feasibility and training, image review and quantitative analysis.

We are proud to support you and bring real precision into the imaging trial, including understanding of pseudo progression and other complex manifestations of the disease in response to treatment.

Our partnerships with oncology focused companies have been published and are available to view on our website at www.ia-grp.com/trial-solutions/bio-partnering/

Reach out to our expert team, as you are designing and planning your trial.

About IAG, Image Analysis Group

IAG, Image Analysis Group is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development, and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed.

Contact our expert team: imaging.experts @ ia-grp.com

READ NEXT CASE STUDY >
Experience: Scoring Systems
  • RECIST1.1, iRECIST, mRECIST, irRC, irRECIST,
  • Volumetric,
  • Radiomics and Multi-Omics,
  • PERCIST and EORTC criteria for PET response,
  • CHOI criteria for response to tumours,
  • Macdonald, RANO, iRANO, mRANO and RAPNO for Neuro-Oncology,
  • PIRADS and PCWG3 criteria for Prostate cancer,
  • Cheson, Lugano and RECIL for lymphoma,
  • Olsen criteria; IWCLL for CLL; MDA for bone metastases
Experience: Imaging
  • CT
  • MRI
  • PET/CT
  • PET/MRI
  • Perfusion imaging (DCE-MRI, DSC)
  • Diffusion imaging (ADC, DWI, DTI)
  • Multiparametric MRI (mpMRI)
  • T-cell Labelling
  • T-Cell Tracing
  • MRI Spectroscopy
  • Breast-based MRI, digital mammography, US, tomosynthesis
  • US
  • Angiography
Publications

Since 2007, over 2000 articles were published to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.

Testimonials

Combining our technologies and business advisory services with promising life science companies has yielded spectacular results over the past five years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words and quotes.